PARAMOUNT: DESCRIPTIVE SUBGROUP ANALYSES OF FINAL OVERALL SURVIVAL (OS) FOR THE PHASE III STUDY OF MAINTENANCE PEMETREXED (PEM) VERSUS PLACEBO (PLB) FOLLOWING INDUCTION TREATMENT WITH PEM PLUS CISPLATIN (CIS) FOR ADVANCED NONSQUAMOUS (NS) NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Reck, M. [1 ]
Paz-Ares, L. [2 ]
De Marinis, F. [3 ]
Molinier, O. [4 ]
Sahoo, T. Prasad [5 ]
Laack, E. [6 ]
John, W. [7 ]
Zimmermann, A. [7 ]
Visseren-Grul, C. M. [8 ]
Gridelli, C. [9 ]
机构：
[1] Hosp Grosshansdorf, Grosshansdorf, Germany
[2] Univ Hosp Virgen del Rocio, Inst Biomed Sevilla 2, Seville, Spain
[3] Azienda Osped S Camillo Forlanini, Pulomonary Oncol Unit 1, Rome, Italy
[4] Le Mans Reg Hosp, Le Mans, France
[5] Jawaharlal Nehru Canc Hosp & Res Ctr, Bhopal, India
[6] Ambulantes Krebszentrum Hamburg, Hamburg, Germany
[7] Eli Lilly & Co, Oncol, Indianapolis, IN 46285 USA
[8] Eli Lilly, Oncol Europe, Ra Houten, Netherlands
[9] UO Oncol Med SG Moscati Hosp, Avellino, Italy
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：404 / 404
页数：1
相关论文
共 50 条
  • [41] Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer
    Schmid-Bindert, Gerald
    Gebbia, Vittorio
    Mayer, Frank
    Arriola, Edurne
    Marquez-Medina, Diego
    Syrigos, Kostas
    Biesma, Bonne
    Leschinger, Monika Iris
    Frimodt-Moller, Bente
    Ripoche, Veronique
    Myrand, Scott P.
    Nguyen, Tuan S.
    Hozak, Rebecca R.
    Zimmermann, Annamaria
    Visseren-Grul, Carla
    Schuette, Wolfgang
    LUNG CANCER, 2013, 81 (03) : 428 - 434
  • [42] COST EFFECTIVENESS OF PEMETREXED/CISPLATIN (PEM/CIS) IN THE TREATMENT OF ADVANCED, NON-SQUAMOUS, NON-SMALL CELL LUNG CANCER (NSQNSCLC) PATIENTS
    Winfree, K. B.
    Shah, M.
    Peterson, P.
    Gruschkus, S.
    Eaddy, M.
    Green, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 428 - 428
  • [43] Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK-positive non-small cell lung cancer (NSCLC)
    Solomon, Benjamin J.
    Gettinger, Scott N.
    Riely, Gregory J.
    Gadgeel, Shirish M.
    Nokihara, Hiroshi
    Han, Ji-Youn
    Hida, Toyoaki
    Satouchi, Miyako
    Baldini, Editta
    Siena, Salvatore
    Yamamoto, Nobuyuki
    Horn, Leora
    Tassell, Vanessa Roberts
    Polli, Anna
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] PHASE III STUDY OF PEMETREXED IN COMBINATION WITH CISPLATIN (PEM/CIS) VERSUS PLACEBO PLUS CISPLATIN (CIS) IN PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL HEAD AND NECK CANCER (HNC)
    Urba, S.
    van Herpen, C. M.
    Sahoo, T. P.
    Shin, D. M.
    Licitra, L.
    Mezei, K.
    Reuter, C.
    Hossain, A. M.
    Chang, S.
    Hong, R.
    ANNALS OF ONCOLOGY, 2010, 21 : 314 - 314
  • [45] Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC)
    Garrido, Pilar
    Engel-Riedel, Walburga
    Serke, Monika
    Giraud, Philippe
    Ricardi, Umberto
    Vallejo, Carmen
    Visseren-Grul, Carla
    Ameryckx, Sophie
    Soldatenkova, Victoria
    Chouaki, Nadia
    Novello, Silvia
    LUNG CANCER, 2015, 88 (02) : 160 - 166
  • [46] Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Pujol, Jean-Louis
    Paz-Ares, Luis
    de Marinis, Filippo
    Dediu, Mircea
    Thomas, Michael
    Bidoli, Paolo
    Corral, Jesus
    San Antonio, Belen
    Chouaki, Nadia
    John, William
    Zimmermann, Annamaria
    Visseren-Grul, Carla
    Gridelli, Cesare
    CLINICAL LUNG CANCER, 2014, 15 (06) : 418 - 425
  • [47] A Dose-Finding and Phase 2 Study of Ruxolitinib plus Pemetrexed/Cisplatin for Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
    Giaccone, Giuseppe
    Sanborn, Rachel
    Waqar, Saiama
    Martinez, Alex
    Ponce, Santiago
    Zhen, Huiling
    Kennealey, Gerard
    Erickson-Viitanen, Susan
    Schaefer, Eric
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S895 - S896
  • [48] Randomized phase II study of pharmacodynamic separation (PDS) of pemetrexed (Pem) and erlotinib (Erl) versus pem alone in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Li, Tianhong
    Piperdi, Bilal
    Walsh, William Vincent
    Kim, Mimi
    Gucalp, Rasim
    Haigentz, Missak
    Bathini, Venu Gopal
    Wu, Xiaoxia
    Pasquinelli, Patricia
    Gajavelli, Srikanth
    Sreedhara, Meera
    Beckett, Laurel A.
    Lara, Primo
    Gandara, David R.
    Perez-Soler, Roman
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [49] The role of cisplatin (CDDP) or carboplatin (CARBO) plus pemetrexed (PEM) in nonsquamous (NON-SQM) non-small cell lung cancer (NSCLC): Results of an Italian retrospective multicentric study.
    Parra, Hector J. Soto
    Favaretto, Adolfo G.
    Bearz, Alessandra
    Cortinovis, Diego Luigi
    Galetta, Domenico
    Cinierl, Saverlo
    Adamo, Vincenzo
    Giannitto-Giorgio, Carmelo
    Tralongo, Paolo
    Barllino, Nicola
    Spada, Massimiliano
    Ferrau, Francesco
    Butera, Alfredo
    Barbieri, Vito
    Blasi, Livio
    Aiello, Marco M.
    Restuccia, Nunzio
    Franchina, Tindara
    Alu, Massimillano
    Bruzzi, Paolo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] Efficacy of Pemetrexed Maintenance in East-Asian Patients Subgroup Analysis of a Phase III Study Comparing Pemetrexed versus Placebo in Non-Small Cell Lung Cancer (NSCLC) Following Platinum-Based Induction Chemotherapy
    Belani, Chandra P.
    Wu, Yi-Long
    Chen, Yuh-Min
    Kim, Joo-Hang
    Yang, Sung-Hyun
    Zhang, Li
    Peterson, Patrick
    Orlando, Mauro
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S373 - S373
12345